NEW YORK and WALTHAM, Mass., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to advancing the next generation of antibody complement therapeutics to treat severe autoimmune diseases, today announced the company’s participation and corporate overview presentations by Marino Garcia, Chief Executive Officer, at the following healthcare investor conferences during the month of September:

• Baird 2024 Global Healthcare Conference on September 11 at 2:00 p.m. ET in New York City
• Cantor 2024 Global Healthcare Conference on September 17 at 10:55 a.m. ET in New York City
• Stifel 2024 Virtual Immunology and Inflammation Summit on September 18 at 10:30 a.m. ET via Zoom

Live webcasts of the Company’s presentations at the Cantor and Stifel conferences may be accessed under “News and Events” in the Investors section of the Dianthus Therapeutics website.

About Dianthus Therapeutics

Dianthus Therapeutics is a clinical-stage biotechnology company dedicated to designing and delivering novel, best-in-class monoclonal antibodies with improved selectivity and potency. Based in New York City and Waltham, Mass., Dianthus is comprised of an experienced team of biotech and pharma executives who are leading the development of next-generation antibody complement therapeutics, aiming to deliver transformative medicines for people living with severe autoimmune and inflammatory diseases.

To learn more, please visit www.dianthustx.com and follow us on LinkedIn.

Contact
Jennifer Davis Ruff
Dianthus Therapeutics
This email address is being protected from spambots. You need JavaScript enabled to view it.